We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0273 | -4.13636363636 | 0.66 | 0.6899 | 0.601 | 41761 | 0.64174913 | CS |
4 | -0.2073 | -24.6785714286 | 0.84 | 0.8583 | 0.601 | 70034 | 0.72808262 | CS |
12 | -0.3573 | -36.0909090909 | 0.99 | 0.99 | 0.601 | 135228 | 0.7949027 | CS |
26 | -0.3573 | -36.0909090909 | 0.99 | 0.99 | 0.601 | 135228 | 0.7949027 | CS |
52 | -0.3573 | -36.0909090909 | 0.99 | 0.99 | 0.601 | 135228 | 0.7949027 | CS |
156 | -0.3573 | -36.0909090909 | 0.99 | 0.99 | 0.601 | 135228 | 0.7949027 | CS |
260 | -0.3573 | -36.0909090909 | 0.99 | 0.99 | 0.601 | 135228 | 0.7949027 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions